<?xml version='1.0' encoding='utf-8'?>
<document id="25845826"><sentence text="Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model." /><sentence text="It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to drug disposition and responses of CYP2C19 substrates during drug development" /><sentence text=" Design of such clinical trials requires projection of genotype-dependent in vivo clearance and associated variabilities of the investigational drug, which is not generally available during early stages of drug development, but is essential for CYP2C19 substrates with multiple clearance pathways" /><sentence text=" This study evaluated the utility of pharmacogenetics-based mechanistic modeling in predicting such parameters" /><sentence text=" Hepatic CYP2C19 activity and variability within genotypes were derived from in vitro S-mephenytoin metabolic activity in genotyped human liver microsomes (N = 128)"><entity charOffset="156-157" id="DDI-PubMed.25845826.s5.e0" text="N" /></sentence><sentence text=" These data were then used in mechanistic models to predict genotype-dependent disposition of CYP2C19 substrates (i" /><sentence text="e" /><sentence text=", S-mephenytoin, citalopram, pantoprazole, and voriconazole) by incorporating in vivo clearance or pharmacokinetics of wild-type subjects and parameters of other clearance pathways"><entity charOffset="2-15" id="DDI-PubMed.25845826.s8.e0" text="S-mephenytoin" /><entity charOffset="17-27" id="DDI-PubMed.25845826.s8.e1" text="citalopram" /><entity charOffset="29-41" id="DDI-PubMed.25845826.s8.e2" text="pantoprazole" /><entity charOffset="47-59" id="DDI-PubMed.25845826.s8.e3" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e0" e2="DDI-PubMed.25845826.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e0" e2="DDI-PubMed.25845826.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e0" e2="DDI-PubMed.25845826.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e0" e2="DDI-PubMed.25845826.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e1" e2="DDI-PubMed.25845826.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e1" e2="DDI-PubMed.25845826.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e1" e2="DDI-PubMed.25845826.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e2" e2="DDI-PubMed.25845826.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25845826.s8.e2" e2="DDI-PubMed.25845826.s8.e3" /></sentence><sentence text=" Relative to the wild-type, the CYP2C19 abundance (coefficient of variation percentage) in CYP2C19*17/*17, *1/*17, *1/*1, *17/null, *1/null, and null/null microsomes was estimated as 1" /><sentence text="85 (117%), 1" /><sentence text="79 (155%), 1" /><sentence text="00 (138%), 0" /><sentence text="83 (80%), 0" /><sentence text="38 (130%), and 0 (0%), respectively" /><sentence text=" The subsequent modeling and simulations predicted, within 2-fold of the observed, the means and variabilities of urinary S/R-mephenytoin ratio (36 of 37 genetic groups), the oral clearance of citalopram (9 of 9 genetic groups) and pantoprazole (6 of 6 genetic groups), and voriconazole oral clearance (4 of 4 genetic groups)"><entity charOffset="193-203" id="DDI-PubMed.25845826.s15.e0" text="citalopram" /><entity charOffset="232-244" id="DDI-PubMed.25845826.s15.e1" text="pantoprazole" /><entity charOffset="274-286" id="DDI-PubMed.25845826.s15.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25845826.s15.e0" e2="DDI-PubMed.25845826.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25845826.s15.e0" e2="DDI-PubMed.25845826.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25845826.s15.e0" e2="DDI-PubMed.25845826.s15.e2" /><pair ddi="false" e1="DDI-PubMed.25845826.s15.e1" e2="DDI-PubMed.25845826.s15.e1" /><pair ddi="false" e1="DDI-PubMed.25845826.s15.e1" e2="DDI-PubMed.25845826.s15.e2" /></sentence><sentence text=" Thus, relative CYP2C19 genotype-dependent hepatic activity and variability were quantified in vitro and used in a mechanistic model to predict pharmacokinetic variability, thus allowing the design of pharmacogenetics and drug-drug interaction trials for CYP2C19 substrates" /><sentence text=" " /></document>